Lukang subsidiary secures marketing authorization for methocarbamol injection

Shandong Lukang Pharmaceutical announced that its controlling subsidiary, Shandong Lukang Pharmaceutical Group Saite Co., Ltd. (Saite Company), has received approval from the National Medical Products Administration for a supplementary application for methocarbamol injection. This approval designates Saite Company as the marketing authorization holder for the drug, a central nervous system depressant used as a muscle relaxant.

The drug, methocarbamol injection (10ml:1g), was previously approved under the national drug approval number H20254371. The transfer of the marketing authorization from Beijing Minkang Baicao Pharmaceutical Technology Co., Ltd. to Saite Company will not change the drug's approval number, production site, formulation, manufacturing process, or quality standards. Saite Company has invested approximately RMB 4.5 million in this technical transfer project to date (unaudited).

According to Pharma Intelligence data, total sales of methocarbamol injection in hospitals nationwide were approximately RMB 213 million in 2022, RMB 280 million in 2023, and RMB 305 million in 2024. The company expects this development to optimize its product structure and maintain stable production capacity to meet market demand, positively impacting its future operations.